Investec Asset Management North America Inc. maintained its position in shares of China Biologic Products, Inc. (NASDAQ:CBPO) during the fourth quarter, Holdings Channel reports. The institutional investor owned 53,371 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Investec Asset Management North America Inc. owned about 0.20% of China Biologic Products worth $5,738,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of CBPO. Westpac Banking Corp bought a new position in China Biologic Products during the third quarter worth approximately $6,894,000. Thomas White International Ltd. boosted its stake in shares of China Biologic Products by 64.7% in the third quarter. Thomas White International Ltd. now owns 72,013 shares of the biopharmaceutical company’s stock worth $8,964,000 after buying an additional 28,295 shares during the period. Granite Point Capital Management L.P. acquired a new stake in shares of China Biologic Products during the third quarter worth about $1,680,000. Greenwoods Asset Management Ltd acquired a new stake in shares of China Biologic Products during the third quarter worth about $2,054,000. Finally, Hermes Investment Management Ltd. boosted its stake in shares of China Biologic Products by 20.5% in the third quarter. Hermes Investment Management Ltd. now owns 321,368 shares of the biopharmaceutical company’s stock worth $40,004,000 after buying an additional 54,641 shares during the period. 70.32% of the stock is owned by institutional investors.
China Biologic Products, Inc. (NASDAQ:CBPO) traded down 0.58% during midday trading on Friday, reaching $114.06. 151,967 shares of the company were exchanged. The company has a 50-day moving average of $111.34 and a 200 day moving average of $116.96. China Biologic Products, Inc. has a 52 week low of $100.53 and a 52 week high of $137.38. The firm has a market capitalization of $3.10 billion, a PE ratio of 31.28 and a beta of 1.78.
ILLEGAL ACTIVITY WARNING: This report was first posted by sleekmoney and is the sole property of of sleekmoney. If you are viewing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this report can be accessed at http://sleekmoney.com/investec-asset-management-north-america-inc-maintains-stake-in-china-biologic-products-inc-cbpo/1655154.html.
A number of brokerages have recently issued reports on CBPO. Jefferies Group LLC reaffirmed a “buy” rating and issued a $155.00 price objective on shares of China Biologic Products in a research note on Friday, November 4th. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th.
About China Biologic Products
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.
Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products, Inc. (NASDAQ:CBPO).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/investec-asset-management-north-america-inc-maintains-stake-in-china-biologic-products-inc-cbpo/1655154.html
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.